Class Action Lawsuit Against Capricor Therapeutics, Inc.
Investors in Capricor Therapeutics, Inc. are now facing a challenging situation as a class action securities lawsuit has been filed against the company. This move, led by the law firm Levi & Korsinsky, LLP, is aimed at securing recoveries for individuals who suffered losses due to the alleged securities fraud that occurred within the company.
Understanding the Class Definition
The class action seeks to represent those investors who were negatively affected by the events surrounding Capricor from October 9, 2024, through July 10, 2025. During this timeframe, the accusations suggest that Capricor misled its shareholders about crucial information regarding its lead cell therapy candidate, deramiocel, designed to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
Allegations of Misleading Information
According to the complaint, Capricor's management allegedly provided misleading information regarding the efficacy and safety data for deramiocel. While publicly stating confidence in the drug's approval process with the U.S. Food and Drug Administration (FDA), the company was reportedly aware of significant deficiencies in its clinical trial data. These discrepancies became evident when the FDA issued a Complete Response Letter (CRL) on July 11, 2025, denying the Biologics License Application (BLA) due to lack of substantial evidence supporting the drug's effectiveness.
Impact on Investors
Following the issuance of the CRL, Capricor's stock price experienced a dramatic decline, dropping from $11.40 per share on July 10, 2025, to $7.64 the following day. This sharp decrease has raised concerns among investors, prompting them to seek legal representation for potential recovery of their losses.
Next Steps for Affected Investors
If you are an investor in Capricor who has experienced a financial setback during the specified period, it’s crucial to act. You have until September 15, 2025, to request that the court appoint you as lead plaintiff in this class action. However, you do not need to take on this role to be eligible for any potential compensation.
No Costs to Participate
One of the most appealing aspects of this class action is that affected investors may be entitled to compensation without incurring any out-of-pocket expenses or legal fees. The firm handling the case, Levi & Korsinsky, emphasizes that there is no financial obligation to participate, making it a viable option for many.
Why Choose Levi & Korsinsky
Levi & Korsinsky boasts an impressive history in securities litigation, having secured hundreds of millions of dollars for harmed shareholders over the past two decades. Their extensive experience positions them as a trusted advocate for investors navigating complex legal challenges. Ranked among the top securities litigation firms, Levi & Korsinsky is dedicated to assisting clients effectively, backed by a skilled team dedicated to providing individualized attention to each case.
Contact Information for Investors
If you wish to explore your options regarding this class action, you can reach out to Joseph E. Levi, Esq. from Levi & Korsinsky at (212) 363-7500. Additionally, potential class members can trust that their inquiries will be managed with the utmost confidentiality and professionalism.
Frequently Asked Questions
What is the purpose of the class action lawsuit against Capricor?
The class action aims to recover losses for investors who were adversely affected by alleged fraudulent statements made by Capricor regarding their lead therapy candidate.
When is the deadline for investors to join the class action?
Investors must act before September 15, 2025, to request to be appointed as lead plaintiff.
What should I do if I invested in Capricor?
If you believe you’ve been impacted, reach out to Levi & Korsinsky for guidance on your potential legal options.
Are there costs associated with joining this class action?
No, there are no costs or fees for class members to participate.
Why should I choose Levi & Korsinsky for representation?
Levi & Korsinsky has a strong track record in securities litigation and is recognized for their dedication to securing justice for shareholders.
